Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection (SPARTA-II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02330445
Recruitment Status : Completed
First Posted : January 5, 2015
Last Update Posted : October 16, 2018
Sponsor:
Information provided by (Responsible Party):
Protalex, Inc.

Brief Summary:

Part A Primary Objective To determine the safety of six months of PRTX-100 administration. Part B Primary Objective To obtain antisera from normal volunteers that have developed anti-PRTX-100 antibodies.

Secondary Objective(s) To assess rheumatoid arthritis activity during the period of PRTX-100 treatment To evaluate the development of anti-PRTX-100 antibodies To explore feasibility of joint evaluations with ultrasound To explore feasibility of biomarkers as disease markers


Condition or disease Intervention/treatment Phase
Arthritis, Rheumatoid Drug: PRTX-100 Phase 1 Phase 2

Detailed Description:

Although the majority of RA patients achieve an amelioration of their RA with older disease modifying agents such as methotrexate and leflunomide, all of these agents provoke adverse events. The newer more active biological agents have a distinct safety profile that includes an increased risk of serious infections. They have an annual treatment expense in the tens of thousands of dollars a year. PRTX-100 may be able to modify the disease course of rheumatoid arthritis with an improved safety profile compared to available agents and a dosing regimen comparable to the therapies currently available. This study is done to describe the adverse event profile of 6 μg/kg of PRTX-100 administered IV for longer periods of treatment that might be required for RA therapy. Secondary objectives include: evaluation of the clinical response of subjects with previous administration of PRTX-100; evaluation of anti-PRTX antibody presence and effect on activity; evaluation of "Power Doppler" ultrasound in the assessment of joint inflammation; and evaluation of biomarkers.

Assay development is an intrinsic part of drug and biological development. The current assay for anti-PRTX-100 antibodies depends on a very limited supply of serum available from individuals in early trials. It will be necessary to obtain adequate antisera to provide immunological reagents for this assay. It is not known whether the character of anti-PRTX-100 antibodies from volunteers is similar to those produced by patients with immunological disorders on cytotoxic therapy. Antisera will be developed in normal volunteers. The anti-PRTX-100 antibody assay will need to be standardized with a new anti-PRTX-100 antibody source compared to the present human reagent.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Two parts of recipients are assigned for this Phase I/II open label, single site study. Part A subjects are all who had RA while Part B subjects are healthy volunteers. All subject are allocated to the single treatment group at a fixed dose of 6.0μg/kg of IV PRTX-100.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers
Study Start Date : February 2015
Actual Primary Completion Date : April 18, 2016
Actual Study Completion Date : November 30, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part A
Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
Drug: PRTX-100
6 micrograms PRTX-100 per kilogram of body weight administered via infusion
Other Names:
  • SpA
  • Staphylococcal Protein A

Experimental: Part B
Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
Drug: PRTX-100
6 micrograms PRTX-100 per kilogram of body weight administered via infusion
Other Names:
  • SpA
  • Staphylococcal Protein A




Primary Outcome Measures :
  1. Safety (Analysis of Adverse Events) [ Time Frame: 6 months ]
    Number, severity, and attribution of relatedness of Adverse Events will be analyzed.


Secondary Outcome Measures :
  1. ACR-28 joint count [ Time Frame: 6 months ]
    ACR 28-joint counts (number of tender and swollen joints) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  2. Patient's global assessment of disease activity [ Time Frame: 6 months ]
    Patient's global assessment of disease activity (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  3. Patient's assessment of pain VAS [ Time Frame: 6 months ]
    Patient's assessment of pain VAS (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  4. Physician's global assessment of disease activity [ Time Frame: 6 months ]
    Physician's global assessment of disease activity (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  5. MDHAQ - Physical Function [ Time Frame: 6 months ]
    MDHAQ Physical Function (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  6. MDHAQ - Joint Pain [ Time Frame: 6 months ]
    MDHAQ Joint Pain (0-48) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  7. MDHAQ - Fatigue [ Time Frame: 6 months ]
    MDHAQ Fatigue (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  8. RAPID 3 [ Time Frame: 6 months ]
    RAPID 3 (0-30) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  9. CDAI [ Time Frame: 6 months ]
    Clinical Disease Activity Index (0-76) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  10. DAS28-CRP [ Time Frame: 6 months ]
    DAS28-CRP (0-10) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  11. hsCRP [ Time Frame: 6 months ]
    C-Reactive Protein (hsCRP) lab values (mg/dL) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  12. ESR [ Time Frame: 6 months ]
    Erythrocyte Sedimentation Rate (mm/hr) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  13. Biomarker Correlation [ Time Frame: 6 months ]
    Vectra-DA scores (1-100) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  14. Disease activity [ Time Frame: 6 months ]
    ACR 28-joint counts (tender and swollen), patient's global assessment of disease activity, patient's assessment of pain VAS, physician's global assessment of disease activity, MDHAQ (overall, physical function, joint pain, and fatigue), RAPID 3, CDAI, DAS28-CRP, CRP, ESR, Vectra-DA, and UPD joint counts, will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  15. Ultrasound Power Doppler Joint Count [ Time Frame: 6 months ]
    UPD joint counts (0-36) will be summarized descriptively by assessment time point in addition to change and percent change from baseline values, as well as in categorical analyses for disease activity.

  16. Immunogenicity [ Time Frame: 6 months ]
    The occurrence of anti-PRTX-100 antibodies (positive/negative) will be summarized descriptively for the observed values and change from baseline results.


Other Outcome Measures:
  1. Sera Collection [ Time Frame: 77 Days ]
    To obtain antisera from normal volunteers that have developed anti-PRTX-100 antibodies.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Part A Inclusion Criteria:

  1. Has completed the written informed consent process
  2. Received PRTX-100 or placebo in Study 104
  3. Receiving methotrexate or leflunomide therapy for at least 12 weeks
  4. Must be on a stable weekly dose of methotrexate (12.5 to 25 mg) or daily leflunomide (10-20 mg/day) by the same route of administration for at least 3 weeks prior to the start of study drug.
  5. Agrees to notify the investigator when deviating from protocol requirements for concomitant medications
  6. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
  7. Agrees to avoid elective surgery for the full duration of the study
  8. For female subjects: agrees to avoid pregnancy from 28 days prior to Study Day 0 and for the full duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide.

Part A Exclusion Criteria:

  1. Diagnosis of any other inflammatory arthritis (e.g. psoriatic arthritis, spondyloarthropathy, gout)
  2. ACR Functional Classification IV
  3. Systemic involvement secondary to rheumatoid arthritis (vasculitis, pulmonary fibrosis or Felty's syndrome. Secondary Sjogren's syndrome is permitted.
  4. Any receipt of abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, tocilizumab or tofacitinib within 3 weeks of Study Day 0
  5. Any receipt of infliximab within 6 weeks of Study Day 0
  6. Any receipt of rituximab or other anti-CD20 antibodies within 12 months of study day 0
  7. Any receipt of another investigational product within 4 weeks or 4 half-lives whichever is longer prior to Study Day 0
  8. Hepatitis B surface antigen positive, HIV positive, hepatitis C antibody positive
  9. Uncontrolled Type 2 Diabetes or Type I diabetes
  10. Positive urine pregnancy test
  11. Diagnosis of hepatic cirrhosis
  12. Urinalysis must reflect no evidence of systemic or local disease process
  13. Severe anemia, defined as < 10 g/dL or hematocrit < 30%
  14. Evidence of significant active infection
  15. Shared a residence within the last year with an individual on anti-tuberculosis treatment or with culture or smear positive tuberculosis
  16. Previous medical history that may compromise the safety of the subject in the study, including but not limited to: severe impairment of pulmonary function or other pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease or poorly controlled epilepsy
  17. Evidence of a new acute illness that may compromise the safety of the subject in the study
  18. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety of the study drug
  19. History or evidence (including chest X-ray) of active tuberculosis
  20. Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol.

Part B Inclusion Criteria

  1. Has completed the written informed consent process
  2. Is in a state of good health
  3. Agrees to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and has no current plans to move from the study area for the duration of the study
  4. Agrees to avoid elective surgery for the full duration of the study
  5. For female subjects: agrees to avoid pregnancy from 28 days prior to Study Day 0 and for the full duration of the study. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods of avoiding pregnancy include a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with spermicide.

Part B Exclusion Criteria

  1. Diagnosis of cancer or autoimmune disease.
  2. Any receipt of another investigational product within 4 weeks or 4 half-lives whichever is longer prior to Study Day 0
  3. Hepatitis B surface antigen positive, HIV positive, hepatitis C antibody positive
  4. Uncontrolled Type 2 Diabetes or Type I diabetes
  5. Diagnosis of hepatic cirrhosis
  6. Positive urine pregnancy test
  7. Urinalysis must reflect no evidence of systemic or local disease process
  8. Severe anemia, defined as < 10 g/dL or hematocrit < 30%
  9. Previous medical history that may compromise the safety of the subject in the study, including but not limited to: severe impairment of pulmonary function or other pulmonary disease; chronic illness with signs of cardiac or renal failure; suspected progressive neurological disease or poorly controlled epilepsy
  10. Evidence of a new acute illness that may compromise the safety of the subject in the study
  11. History or evidence on physical examination of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may interfere with the evaluation of the safety of the study drug
  12. Any current medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02330445


Locations
Layout table for location information
United States, Idaho
Protalex Investigational Site
Coeur d'Alene, Idaho, United States, 83814
Sponsors and Collaborators
Protalex, Inc.
Investigators
Layout table for investigator information
Study Director: John B McClain, MD Protalex, Inc.

Layout table for additonal information
Responsible Party: Protalex, Inc.
ClinicalTrials.gov Identifier: NCT02330445     History of Changes
Other Study ID Numbers: PRTX-100-105
First Posted: January 5, 2015    Key Record Dates
Last Update Posted: October 16, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases